2.97
+0.02(+0.68%)
Currency In USD
| Previous Close | 2.95 |
| Open | 2.92 |
| Day High | 3.05 |
| Day Low | 2.93 |
| 52-Week High | 4.14 |
| 52-Week Low | 2.46 |
| Volume | 565,141 |
| Average Volume | 384,606 |
| Market Cap | 254.17M |
| PE | -1.8 |
| EPS | -1.65 |
| Moving Average 50 Days | 2.89 |
| Moving Average 200 Days | 3.23 |
| Change | 0.02 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $97.89 as of June 01, 2025 at a share price of $2.97. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $402.44 as of June 01, 2025 at a share price of $2.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Ate
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
GlobeNewswire Inc.
Apr 23, 2025 11:00 AM GMT
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, t